MANE

Veradermics is a clinical-stage biopharma with zero product revenue, an accumulated deficit of $123.4M, and a single lead asset (VDPHL01, an extended-release oral minoxidil for pattern hair loss) carrying the entire equity story. FY2025 net loss widened to $70.0M from $26.5M (YoY -164.3%) as R&D scaled to $62.1M (+166.6%) ahead of two registration-directed trials. Operating cash burn of $71.6M against just $21.8M of cash at year-end would have been existential, but the 10-K discloses a Q4 2025 Series C raising $151.0M gross and a Q1 2026 IPO netting $269.7M at $17.00/share — together extending runway materially beyond the balance-sheet snapshot.

The valuation problem is acute. At $117.29 the stock trades at ~6.9x the $17.00 IPO price set just months ago, with today's +13.21% move suggesting momentum/speculation rather than fundamentals. There is no revenue to anchor a P/S multiple, no earnings for P/E (diluted EPS is -$111.91 on the pre-IPO share count), and the reported -$121M stockholders' equity reflects the redeemable convertible preferred structure pre-IPO — making the headline 'ROE 57.8%' and 'liabilities/equity -0.08x' mechanically meaningless. The true post-IPO capital structure is not in these numbers.